Russian Journal of BiotherapyRussian Journal of BiotherapyРоссийский биотерапевтический журнал1726-97841726-9792Publishing House ABV Press146910.17650/1726-9784-2024-23-3-18-25REVIEWОБЗОР ЛИТЕРАТУРЫSerum proteins as predictors of the development of chemotherapy-induced peripheral neuropathyСывороточные белки как предикторы развития химиоиндуцированной полинейропатииhttps://orcid.org/0000-0002-1796-0193TikhonovaO. A.ТихоноваО. А.
Russian Federation

Olga Alekseevna Tikhonova

4 A. Nevskogo St., Kaliningrad 236041

Ольга Алексеевна Тихонова

236041 Калининград, ул. А. Невского, 14

offelia78@mail.ruhttps://orcid.org/0000-0002-1004-992XDruzhininаE. S.ДружининаЕ. С.
Russian Federation

Evgenia S. Druzhininа

1A Ostrovityanova St., Moscow 117513

 117513 Москва, ул. Островитянова, 1A

https://orcid.org/0000-0003-1480-1311TuchinaO. P.ТучинаО. П.
Russian Federation

Oksana P. Tuchina

4 A. Nevskogo St., Kaliningrad 236041

236041 Калининград, ул. А. Невского, 14

https://orcid.org/0000-0002-6244-0867DruzhininD. S.ДружининД. С.
Russian Federation

Dmitry S. Druzhinin

6 Revolutionnaya St., Yaroslavl 150000

150000 Ярославль, ул. Революционная, 6

https://orcid.org/0000-0001-5858-7877DoktorovaS. A.ДоктороваС. А.
Russian Federation

Svetlana A. Doktorova

4 A. Nevskogo St., Kaliningrad 236041

236041 Калининград, ул. А. Невского, 14

Immanuel Kant Baltic Federal UniversityФГАОУ ВО «Балтийский федеральный университет им. Иммануила Канта»N.I. Pirogov Russian National Research Medical University, Ministry of Health of RussiaФГБОУ ВО «Российский национальный исследовательский медицинский университет им. Н. И. Пирогова» Минздрава РоссииYaroslavl State Medical University, Ministry of Health of RussiaФГБОУ ВО «Ярославский государственный медицинский университет» Минздрава России0710202423318250310202403102024https://bioterapevt.abvpress.ru/jour/article/view/1469

Background. The development of polyneuropathy in the context of cytotoxic drug administration is a common neurological complication that can significantly impair patients’ quality of life and limit the use of chemotherapy. The difficulties in predicting the manifestations and severity of neurological complications are due to multiple factors, including individual patient characteristics, the type and dosage of the drug used, as well as the presence of comorbid conditions. In recent years, researchers have focused on identifying serum biomarkers that may aid in the early diagnosis and monitoring of Сhemotherapy-induced Peripheral Neuropathy. Understanding their role in the development of polyneuropathy may open new avenues for developing strategies for the prevention and treatment of this complication, which, in turn, could enhance treatment efficacy and improve patients’ quality of life. This review is dedicated to biomarkers and their clinical significance in the development of Сhemotherapy induced Peripheral Neuropathy.

Aim. To analyze and summarize the current understanding of serum biological markers of Chemotherapy-induced Peripheral Neuropathy based on literature data.

Materials and methods. The literature search was performed using the following databases: PubMed, Medline. Systematic reviews, publications of original studies and meta-analyses between 2000 and 2023 were included in the analysis.

Results. Over the past decades, new insights in to the role of biomarkers in the development of Chemotherapy-induced Peripheral Neuropathy have emerged, among which neurofilaments are more specific. The use of readily available and ultra-sensitive techniques for measuring biomarker concentrations will allow early prediction and prevention of this complication.

Conclusion. The analysis of literature data has shown the high relevance of the role of biomarkers in the damage of peripheral nervous system structures, which may in the near future affect the management tactics and in turn improve the quality of life of cancer patients.

Введение. Развитие полинейропатии на фоне применения цитотоксических препаратов является частым неврологическим осложнением, которое может значительно ухудшить качество жизни пациентов и ограничить возможности использования химиотерапии. Трудности в прогнозировании проявлений и тяжести неврологических осложнений обусловлены множеством факторов, включая индивидуальные особенности пациента, тип и дозу применяемого препарата, а также наличие сопутствующих заболеваний. В последние годы внимание исследователей сосредоточилось на выявлении сывороточных биомаркеров, которые могут помочь в ранней диагностике и мониторинге химиоиндуцированной полинейропатии. Понимание их роли в развитии полинейропатииможетоткрытьновыевозможностидляразработкистратегийпрофилактикиилеченияданногоосложнения, что, в свою очередь, может повысить эффективность лечения и улучшить качество жизни пациентов. Данный обзор посвящен биомаркерам и их клиническому значению в развитии химиоиндуцированной полинейропатии.

Цель исследования – анализ и обобщение современных представлений о сывороточных биологических маркерах химиоиндуцированной полинейропатии на основании данных литературы.

Материалы и методы. Поиск литературы проводили с использованием баз данных PubMed и Medline.В анализ включали систематические обзоры, публикации оригинальных исследований и метаанализы в период с 2000 по 2023 г.

Результаты. За последние десятилетия появилось новое понимание роли биомаркеров в развитии химиоиндуцированной полинейропатии, среди которых наиболее специфичными являются нейрофиламенты. Использование доступных и чувствительных методик измерения концентрации биомаркеров позволит на ранней стадии прогнозировать и предотвращать развитие данного осложнения.

Заключение.Анализданныхлитературыпоказалвысокуюзначимостьбиомаркеровприповрежденииструктур периферической нервной системы, что может в ближайшем будущем отразиться на тактике ведения онкологических пациентов и, в свою очередь, улучшит качество их жизни.

chemotherapy-induced peripheral neuropathybiomarkersneurofilamentswhey proteinsхимиоиндуцированная полинейропатиябиомаркерынейрофиламентысывороточные белкиThis his work was supported from the Russian Federal Academic Leadership Program “Priority 2030” at the Immanuel Kant Baltic Federal University.Данная работа была поддержана из средств программы стратегического академического лидерства «Приоритет 2030» БФУ им. И. Канта.1. Zedan A.H., Vilholm O.J. Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires. Basic Clin Pharmacol Toxicol 2014;115(2):193–200. DOI:10.1111/bcpt.12262Zedan A.H., Vilholm O.J. Chemotherapy-induced polyneuropathy: major agents and assessment by questionnaires. Basic Clin Pharmacol Toxicol 2014;115(2):193–200. DOI:10.1111/bcpt.122622. Seretny M., Currie G.L., Sena E.S. et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain 2014;155(12):2461–70. DOI: 10.1016/j.pain.2014.09.020Seretny M., Currie G.L., Sena E.S. et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain 2014;155(12):2461–70. DOI: 10.1016/j.pain.2014.09.0203. Cavaletti G., Alberti P., Frigeni B. et al. Chemotherapy-induced neuropathy. Curr Treat Options Neurol 2011;13(2):180–90. DOI:10.1007/s11940-010-0108-3Cavaletti G., Alberti P., Frigeni B. et al. Chemotherapy-induced neuropathy. Curr Treat Options Neurol 2011;13(2):180–90. DOI:10.1007/s11940-010-0108-34. Choi J., Kong K., Mozaffar T., Holcombe R.F. Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anticancer Drugs 2006;17(1):103–5. DOI: 10.1097/01.cad.0000185185.64980.70Choi J., Kong K., Mozaffar T., Holcombe R.F. Delayed oxaliplatin-associated neurotoxicity following adjuvant chemotherapy for stage III colon cancer. Anticancer Drugs 2006;17(1):103–5. DOI: 10.1097/01.cad.0000185185.64980.705. Quasthoff S., Hartung H.P. Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249(1):9–17. DOI: 10.1007/pl00007853Quasthoff S., Hartung H.P. Chemotherapy-induced peripheral neuropathy. J Neurol 2002;249(1):9–17. DOI: 10.1007/pl000078536. Colvin L.A. Chemotherapy-induced peripheral neuropathy (CIPN): where are we now? Pain 2019;160:S1. DOI: 10.1097/j.pain.0000000000001540Colvin L.A. Chemotherapy-induced peripheral neuropathy (CIPN): where are we now? Pain 2019;160:S1. DOI: 10.1097/j.pain.00000000000015407. Loprinzi C.L., Lacchetti C., Bleeker J. et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325–48. DOI:10.1200/JCO.20.01399Loprinzi C.L., Lacchetti C., Bleeker J. et al. Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: ASCO Guideline Update. J Clin Oncol 2020;38(28):3325–48. DOI:10.1200/JCO.20.013998. Hertz D.L., Childs D.S., Park S.B. et al. Patient-centric decision framework for treatment alterations in patients with chemotherapy-induced peripheral neuropathy (CIPN). Cancer Treat Rev 2021;99:102241. DOI: 10.1016/j.ctrv.2021.102241Hertz D.L., Childs D.S., Park S.B. et al. Patient-centric decision framework for treatment alterations in patients with chemotherapy-induced peripheral neuropathy (CIPN). Cancer Treat Rev 2021;99:102241. DOI: 10.1016/j.ctrv.2021.1022419. Delaby C., Alcolea D., Carmona-Iragui M. et al. Differential levels of neurofilament light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Sci Rep 2020;10(1):9161. DOI: 10.1038/s41598-020-66090-xDelaby C., Alcolea D., Carmona-Iragui M. et al. Differential levels of neurofilament light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders. Sci Rep 2020;10(1):9161. DOI: 10.1038/s41598-020-66090-x10. Kim S-H., Choi M.K., Park N.Y. et al. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci Rep 2020;10(1):7995. DOI:10.1038/s41598-020-64511-5Kim S-H., Choi M.K., Park N.Y. et al. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci Rep 2020;10(1):7995. DOI:10.1038/s41598-020-64511-511. Huehnchen P., Schinke C., Bangemann N. et al. Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. JCI Insight 2022;7(6):e154395. DOI: 10.1172/jci.insight.154395Huehnchen P., Schinke C., Bangemann N. et al. Neurofilament proteins as a potential biomarker in chemotherapy-induced polyneuropathy. JCI Insight 2022;7(6):e154395. DOI: 10.1172/jci.insight.15439512. Kim S.H., Kim K.H., Hyun J.W. et al. Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxelinduced peripheral neuropathy in patients with gynecological cancers. Front Oncol 2022;12:942960. DOI: 10.3389/fonc.2022.942960Kim S.H., Kim K.H., Hyun J.W. et al. Blood neurofilament light chain as a biomarker for monitoring and predicting paclitaxelinduced peripheral neuropathy in patients with gynecological cancers. Front Oncol 2022;12:942960. DOI: 10.3389/fonc.2022.94296013. Meregalli C., Fumagalli G., Alberti P. et al. Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of chemotherapy-induced peripheral neurotoxicity. Arch Toxicol 2020;94(7):2517–22. DOI:10.1007/s00204-020-02755-wMeregalli C., Fumagalli G., Alberti P. et al. Neurofilament light chain: a specific serum biomarker of axonal damage severity in rat models of chemotherapy-induced peripheral neurotoxicity. Arch Toxicol 2020;94(7):2517–22. DOI:10.1007/s00204-020-02755-w14. Burgess B.L., Cho E., Honigberg L. Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin. Sci Rep 2022;12(1):15593. DOI: 10.1038/s41598-022-18716-5Burgess B.L., Cho E., Honigberg L. Neurofilament light as a predictive biomarker of unresolved chemotherapy-induced peripheral neuropathy in subjects receiving paclitaxel and carboplatin. Sci Rep 2022;12(1):15593. DOI: 10.1038/s41598-022-18716-515. Romano R., Del Fiore V.S., Bucci C. Role of the intermediate filament protein peripherin in health and disease. Int J Mol Sci 2022;23(23):15416. DOI:10.3390/ijms232315416Romano R., Del Fiore V.S., Bucci C. Role of the intermediate filament protein peripherin in health and disease. Int J Mol Sci 2022;23(23):15416. DOI:10.3390/ijms23231541616. Yuan A., Sasaki T., Kumar A. et al. Peripherin is a subunit of peripheral nerve neurofilaments: implications for differential vulnerability of CNS and peripheral nervous system axons. J Neurosci 2012;32(25):8501–8. DOI: 10.1523/JNEUROSCI.1081-12.2012Yuan A., Sasaki T., Kumar A. et al. Peripherin is a subunit of peripheral nerve neurofilaments: implications for differential vulnerability of CNS and peripheral nervous system axons. J Neurosci 2012;32(25):8501–8. DOI: 10.1523/JNEUROSCI.1081-12.201217. Keddie S., Smyth D., Keh R.Y.S. et al. Peripherin is a biomarker of axonal damage in peripheral nervous system disease. Brain 2023;146(11):4562–73. DOI:10.1093/brain/awad234Keddie S., Smyth D., Keh R.Y.S. et al. Peripherin is a biomarker of axonal damage in peripheral nervous system disease. Brain 2023;146(11):4562–73. DOI:10.1093/brain/awad23418. Meregalli C., Bonomo R., Cavaletti G., Carozzi V.A. Blood molecular biomarkers for chemotherapy-induced peripheral neuropathy: from preclinical models to clinical practice. Neurosci Lett 2021;749:135739. DOI: 10.1016/j.neulet.2021.135739Meregalli C., Bonomo R., Cavaletti G., Carozzi V.A. Blood molecular biomarkers for chemotherapy-induced peripheral neuropathy: from preclinical models to clinical practice. Neurosci Lett 2021;749:135739. DOI: 10.1016/j.neulet.2021.13573919. Youk J., Kim Y.S., Lim J.A. et al. Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies. PLoS One 2017;12(8):e0183491. DOI: 10.1371/journal.pone.0183491Youk J., Kim Y.S., Lim J.A. et al. Depletion of nerve growth factor in chemotherapy-induced peripheral neuropathy associated with hematologic malignancies. PLoS One 2017;12(8):e0183491. DOI: 10.1371/journal.pone.018349120. Omar N.A., Kumar J., Teoh S.L. Neurotrophin-3 and neurotrophin-4: The unsung heroes that lies behind the meninges. Neuropeptides 2022;92:102226. DOI: 10.1016/j.npep.2022.102226Omar N.A., Kumar J., Teoh S.L. Neurotrophin-3 and neurotrophin-4: The unsung heroes that lies behind the meninges. Neuropeptides 2022;92:102226. DOI: 10.1016/j.npep.2022.10222621. Aloe L, Rocco ML, Bianchi P, Manni L. Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med 2012;10:239. DOI: 10.1186/1479-5876-10-239Aloe L, Rocco ML, Bianchi P, Manni L. Nerve growth factor: from the early discoveries to the potential clinical use. J Transl Med 2012;10:239. DOI: 10.1186/1479-5876-10-23922. De Santis S., Pace A., Bove L. et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res 2000;6(1):90–5. PMID: 10656436De Santis S., Pace A., Bove L. et al. Patients treated with antitumor drugs displaying neurological deficits are characterized by a low circulating level of nerve growth factor. Clin Cancer Res 2000;6(1):90–5. PMID: 1065643623. Velasco R., Navarro X., Gil-Gil M. et al. Neuropathic pain and nerve growth factor in chemotherapy-induced peripheral neuropathy: prospective clinical-pathological study. J Pain Symptom Manage 2017;54(6):815–25. DOI: 10.1016/j.jpainsymman.2017.04.021Velasco R., Navarro X., Gil-Gil M. et al. Neuropathic pain and nerve growth factor in chemotherapy-induced peripheral neuropathy: prospective clinical-pathological study. J Pain Symptom Manage 2017;54(6):815–25. DOI: 10.1016/j.jpainsymman.2017.04.02124. Wang X., Ratnam J., Zou B. et al. TrkB signaling is required for both the induction and maintenance of tissue and nerve injury-induced persistent pain. J Neurosci 2009;29(17):5508–15. DOI: 10.1523/JNEUROSCI.4288-08.2009Wang X., Ratnam J., Zou B. et al. TrkB signaling is required for both the induction and maintenance of tissue and nerve injury-induced persistent pain. J Neurosci 2009;29(17):5508–15. DOI: 10.1523/JNEUROSCI.4288-08.200925. Szudy-Szczyrek A., Mlak R., Bury-Kamińska M. et al. Serum brain-derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients. Br J Haematol 2020;191(1):77–89. DOI: 10.1111/bjh.16862Szudy-Szczyrek A., Mlak R., Bury-Kamińska M. et al. Serum brain-derived neurotrophic factor (BDNF) concentration predicts polyneuropathy and overall survival in multiple myeloma patients. Br J Haematol 2020;191(1):77–89. DOI: 10.1111/bjh.1686226. Azoulay D., Giryes S., Nasser R. et al. Prediction of chemotherapy-induced peripheral neuropathy in patients with lymphoma and myeloma: the roles of brain-derived neurotropic factor protein levels and A gene polymorphism. J Clin Neurol 2019;15(4):511–6. DOI: 10.3988/jcn.2019.15.4.511Azoulay D., Giryes S., Nasser R. et al. Prediction of chemotherapy-induced peripheral neuropathy in patients with lymphoma and myeloma: the roles of brain-derived neurotropic factor protein levels and A gene polymorphism. J Clin Neurol 2019;15(4):511–6. DOI: 10.3988/jcn.2019.15.4.51127. Tonyan S., Pospelova M., Krasnikova V. et al. Neurotrophin-3 (NT-3) as a potential biomarker of the peripheral nervous system damage following breast cancer treatment. Pathophysiology 2023;30(2):110–22. DOI: 10.3390/pathophysiology30020010Tonyan S., Pospelova M., Krasnikova V. et al. Neurotrophin-3 (NT-3) as a potential biomarker of the peripheral nervous system damage following breast cancer treatment. Pathophysiology 2023;30(2):110–22. DOI: 10.3390/pathophysiology3002001028. Wilson-Gerwing T.D., Dmyterko M.V., Zochodne D.W. et al. Neurotrophin-3 suppresses thermal hyperalgesia associated with neuropathic pain and attenuates transient receptor potential vanilloid receptor-1 expression in adult sensory neurons. J Neurosci 2005;25(3):758–67. DOI: 10.1523/JNEUROSCI.3909-04.2005Wilson-Gerwing T.D., Dmyterko M.V., Zochodne D.W. et al. Neurotrophin-3 suppresses thermal hyperalgesia associated with neuropathic pain and attenuates transient receptor potential vanilloid receptor-1 expression in adult sensory neurons. J Neurosci 2005;25(3):758–67. DOI: 10.1523/JNEUROSCI.3909-04.200529. Hernández-Echeagaray E. Neurotrophin-3 modulates synaptic transmission. Vitam Horm 2020;114:71–89. DOI: 10.1016/bs.vh.2020.04.008Hernández-Echeagaray E. Neurotrophin-3 modulates synaptic transmission. Vitam Horm 2020;114:71–89. DOI: 10.1016/bs.vh.2020.04.00830. Gandhi R., Ryals J.M., Wright D.E. Neurotrophin-3 reverses chronic mechanical hyperalgesia induced by intramuscular acid injection. J Neurosci 2004;24(42):9405–13. DOI: 10.1523/JNEUROSCI.0899-04.2004Gandhi R., Ryals J.M., Wright D.E. Neurotrophin-3 reverses chronic mechanical hyperalgesia induced by intramuscular acid injection. J Neurosci 2004;24(42):9405–13. DOI: 10.1523/JNEUROSCI.0899-04.200431. Wilson-Gerwing T.D., Stucky C.L., McComb G.W., Verge V.M. Neurotrophin-3 significantly reduces sodium channel expression linked to neuropathic pain states. Exp Neurol 2008;213(2):303–14. DOI: 10.1016/j.expneurol.2008.06.002Wilson-Gerwing T.D., Stucky C.L., McComb G.W., Verge V.M. Neurotrophin-3 significantly reduces sodium channel expression linked to neuropathic pain states. Exp Neurol 2008;213(2):303–14. DOI: 10.1016/j.expneurol.2008.06.00232. Sahenk Z., Nagaraja H.N., McCracken B.S. et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 2005;65(5):681–9. DOI: 10.1212/01.wnl.0000171978.70849.c5Sahenk Z., Nagaraja H.N., McCracken B.S. et al. NT-3 promotes nerve regeneration and sensory improvement in CMT1A mouse models and in patients. Neurology 2005;65(5):681–9. DOI: 10.1212/01.wnl.0000171978.70849.c533. Chaudhry V., Giuliani M., Petty B.G. et al. Tolerability of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy subjects. Muscle Nerve 2000;23(2):189–92. DOI: 10.1002/(sici)1097-4598(200002)23:23.0.co;2-8Chaudhry V., Giuliani M., Petty B.G. et al. Tolerability of recombinant-methionyl human neurotrophin-3 (r-metHuNT3) in healthy subjects. Muscle Nerve 2000;23(2):189–92. DOI: 10.1002/(sici)1097-4598(200002)23:23.0.co;2-834. Xu X., Song L., Li Y. et al. Neurotrophin-3 promotes peripheral nerve regeneration by maintaining a repair state of Schwann cells after chronic denervation via the TrkC/ ERK/c-Jun pathway. J Transl Med 2023;21(1):733. DOI:10.1186/s12967-023-04609-2Xu X., Song L., Li Y. et al. Neurotrophin-3 promotes peripheral nerve regeneration by maintaining a repair state of Schwann cells after chronic denervation via the TrkC/ ERK/c-Jun pathway. J Transl Med 2023;21(1):733. DOI:10.1186/s12967-023-04609-235. Srejovic I., Selakovic D., Jovicic N. et al. Galectin-3: roles in neurodevelopment, neuroinflammation, and behavior. Biomolecules 2020;10(5):798. DOI:10.3390/biom10050798Srejovic I., Selakovic D., Jovicic N. et al. Galectin-3: roles in neurodevelopment, neuroinflammation, and behavior. Biomolecules 2020;10(5):798. DOI:10.3390/biom1005079836. Burguillos M.A., Svensson M., Schulte T. et al. Microgliasecreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation. Cell Rep 2015;10(9):1626–38. DOI: 10.1016/j.celrep.2015.02.012Burguillos M.A., Svensson M., Schulte T. et al. Microgliasecreted galectin-3 acts as a toll-like receptor 4 ligand and contributes to microglial activation. Cell Rep 2015;10(9):1626–38. DOI: 10.1016/j.celrep.2015.02.01237. Ma Z., Han Q., Wang X. et al. Galectin-3 inhibition is associated with neuropathic pain attenuation after peripheral nerve injury. PLoS One 2016;11(2):e0148792. DOI: 10.1371/journal.pone.0148792Ma Z., Han Q., Wang X. et al. Galectin-3 inhibition is associated with neuropathic pain attenuation after peripheral nerve injury. PLoS One 2016;11(2):e0148792. DOI: 10.1371/journal.pone.014879238. Koyanagi M., Imai S., Matsumoto M. et al. Pronociceptive roles of Schwann cell-derived galectin-3 in taxane-induced peripheral neuropathy. Cancer Res 2021;81(8):2207–19. DOI: 10.1158/0008-5472.CAN-20-2799Koyanagi M., Imai S., Matsumoto M. et al. Pronociceptive roles of Schwann cell-derived galectin-3 in taxane-induced peripheral neuropathy. Cancer Res 2021;81(8):2207–19. DOI: 10.1158/0008-5472.CAN-20-279939. Sommer C., Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 2004;361(1-3):184–7. DOI: 10.1016/j.neulet.2003.12.007Sommer C., Kress M. Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia. Neurosci Lett 2004;361(1-3):184–7. DOI: 10.1016/j.neulet.2003.12.00740. Tofaris G.K., Patterson P.H., Jessen K.R., Mirsky R. Denervated Schwann cells attract macrophages by secretion of leukemia inhibitory factor (LIF) and monocyte chemoattractant protein-1 in a process regulated by interleukin-6 and LIF. J Neurosci 2002;22(15):6696–703. DOI: 10.1523/JNEUROSCI.22-15-06696.2002Tofaris G.K., Patterson P.H., Jessen K.R., Mirsky R. Denervated Schwann cells attract macrophages by secretion of leukemia inhibitory factor (LIF) and monocyte chemoattractant protein-1 in a process regulated by interleukin-6 and LIF. J Neurosci 2002;22(15):6696–703. DOI: 10.1523/JNEUROSCI.22-15-06696.200241. Wang X.M., Lehky T.J. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine 2012;59(1):3–9. DOI: 10.1016/j.cyto.2012.03.027Wang X.M., Lehky T.J. Discovering cytokines as targets for chemotherapy-induced painful peripheral neuropathy. Cytokine 2012;59(1):3–9. DOI: 10.1016/j.cyto.2012.03.02742. Illias A.M., Gist A.C., Zhang H. et al. Chemokine CCL2 and its receptor CCR2 in the dorsal root ganglion contribute to oxaliplatin-induced mechanical hypersensitivity. Pain 2018; 159(7):1308–16. DOI: 10.1097/j.pain.0000000000001212Illias A.M., Gist A.C., Zhang H. et al. Chemokine CCL2 and its receptor CCR2 in the dorsal root ganglion contribute to oxaliplatin-induced mechanical hypersensitivity. Pain 2018; 159(7):1308–16. DOI: 10.1097/j.pain.000000000000121243. Schäfers M., Brinkhoff J., Neukirchen S. et al. Combined epineurial therapy with neutralizing antibodies to tumor necrosis factor-alpha and interleukin-1 receptor has an additive effect in reducing neuropathic pain in mice. Neurosci Lett 2001;310(2-3): 113–6. DOI: 10.1016/s0304-3940(01)02077-8Schäfers M., Brinkhoff J., Neukirchen S. et al. Combined epineurial therapy with neutralizing antibodies to tumor necrosis factor-alpha and interleukin-1 receptor has an additive effect in reducing neuropathic pain in mice. Neurosci Lett 2001;310(2-3): 113–6. DOI: 10.1016/s0304-3940(01)02077-844. Liu C.C., Lu N., Cui Y. et al. Prevention of paclitaxel-induced allodynia by minocycline: effect on loss of peripheral nerve fibers and infiltration of macrophages in rats. Mol Pain 2010;6:76. DOI: 10.1016/s0304-3940(01)02077-8Liu C.C., Lu N., Cui Y. et al. Prevention of paclitaxel-induced allodynia by minocycline: effect on loss of peripheral nerve fibers and infiltration of macrophages in rats. Mol Pain 2010;6:76. DOI: 10.1016/s0304-3940(01)02077-845. Boyette-Davis J., Dougherty P.M. Protection against oxaliplatininduced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline. Exp Neurol 2011;229(2):353–7. DOI: 10.1016/j.expneurol.2011.02.019Boyette-Davis J., Dougherty P.M. Protection against oxaliplatininduced mechanical hyperalgesia and intraepidermal nerve fiber loss by minocycline. Exp Neurol 2011;229(2):353–7. DOI: 10.1016/j.expneurol.2011.02.01946. Castello L.M., Raineri D., Salmi L. et al. Osteopontin at the crossroads of inflammation and tumor progression. Mediators Inflamm 2017;2017:4049098. DOI: 10.1155/2017/4049098Castello L.M., Raineri D., Salmi L. et al. Osteopontin at the crossroads of inflammation and tumor progression. Mediators Inflamm 2017;2017:4049098. DOI: 10.1155/2017/404909847. Pizzamiglio C., Ripellino P., Prandi P. et al. Nerve conduction, circulating osteopontin and taxane-induced neuropathy in breast cancer patients. Neurophysiol Clin 2020;50(1):47–54. DOI: 10.1016/j.neucli.2019.12.001Pizzamiglio C., Ripellino P., Prandi P. et al. Nerve conduction, circulating osteopontin and taxane-induced neuropathy in breast cancer patients. Neurophysiol Clin 2020;50(1):47–54. DOI: 10.1016/j.neucli.2019.12.00148. Lund S.A., Wilson C.L., Raines E.W. et al. Osteopontin mediates macrophage chemotaxis via α4 and α9 integrins and survival via the α4 integrin. J Cell Biochem 2013;114(5):1194–202. DOI:10.1002/jcb.24462Lund S.A., Wilson C.L., Raines E.W. et al. Osteopontin mediates macrophage chemotaxis via α4 and α9 integrins and survival via the α4 integrin. J Cell Biochem 2013;114(5):1194–202. DOI:10.1002/jcb.2446249. Hu S., Huang K.M., Adams E.J. et al. Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin Cancer Res 2019;25(21):6295–301. DOI: 10.1158/1078-0432.CCR-18-2152Hu S., Huang K.M., Adams E.J. et al. Recent developments of novel pharmacologic therapeutics for prevention of chemotherapy-induced peripheral neuropathy. Clin Cancer Res 2019;25(21):6295–301. DOI: 10.1158/1078-0432.CCR-18-2152